Company: INMB
Filing Date: 2025-02-10
Form Type: 8-K
Source: 0001213900-25-011733
Chunk: 4

Company: Inmune Bio, Inc.
Filing Date: 2025-02-10
Form: 8-K
Item: Item 9.01
Chunk 4
---
Item
9.01 Financial Statements and Exhibits.

(d) Exhibits

  Exhibit      Description                                                                                                                                     
      No.                                                                                                                                                      
     10.1      License Agreement, dated February 6, 2025, between INmune Bio Inc. and Great Ormond Street Hospital for Children NHS Foundation Trust           
     10.2      Termination Letter, dated February 6, 2025, between INmune Bio Inc. and Silicon Valley Bank, a division of First-Citizens Bank & Trust Company  
     99.1      Press Release, dated February 10, 2025                                                                                                          
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
      104      Cover Page Interactive Data File (embedded within the Inline XBRL document)                                                                     

SIGNATURES

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                               INMUNE BIO INC.                               
  Date: February 10, 2025      By:                  /s/ David Moss           
                               Name:                David Moss               
                               Title:               Chief Financial Officer